Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04380207 · ClinicalTrials.gov registry record · Phase 1
P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
A Phase 1 study of Bacterial Infections, sponsored by Qpex Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 2
- Study locations
NCT04380207 is a Phase 1 study of Bacterial Infections that has completed, run by Qpex Biopharma. The registered enrollment target is 82 participants, below the 136-participant average among 17 other Bacterial Infections trials with a reported enrollment target (40% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04380207, a Phase 1 study of Bacterial Infections, has completed, sponsored by Qpex Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 2
- Study locations
Study Summary
QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor, with activity against numerous beta-lactamases, including class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and extended spectrum class D oxacillinases (OXA) that can hydrolyze cephalosporins and can be found in Enterobacteriaceae and Pseudomonas aeruginosa (P. aeruginosa). QPX7728 is also a potent inhibitor of carbapenemases from all molecular classes, such as class A Klebsiella pheumoniae carbapenemase (KPC), class B New-Dehli Metalo-beta-lactamase (NDM) and Verona integron-encoded metallo-beta-lactamase (VIM), and class D OXA-48 that are found in carbapenem resistant Enterobacteriaceae, and also class D carbapenemases such as OXA-23 that are found in carbapenem resistant Acinetobacter baumannii.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG QPX7728
- DRUG QPX2014
Study Locations (2)
California
- Altasciences - Cypress
South Australia
- CMAX - Adelaide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2020-11-24 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04380207
The ClinicalTrials.gov registry entry for NCT04380207 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 136-participant average among 17 other Bacterial Infections trials with a reported enrollment target (40% lower). The listed sponsor is Qpex Biopharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bacterial Infections appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04380207 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, South Australia.
Frequently Asked Questions
What is clinical trial NCT04380207 about?
NCT04380207 is a clinical study titled "P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV". QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor, with activity against numerous beta-lactamases, including class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and extended spectrum class D oxacillinases (OXA) that can hydrolyze cephalosporins and can be found in...
What is the current status of trial NCT04380207?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2020-11-24. Estimated completion is 2022-08-31.
What conditions does trial NCT04380207 study?
This clinical trial studies the following conditions: Bacterial Infections.
What interventions are being tested in trial NCT04380207?
The interventions under investigation include: Placebo (DRUG), QPX7728 (DRUG), QPX2014 (DRUG).
Who is sponsoring clinical trial NCT04380207?
This trial is sponsored by Qpex Biopharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04380207 being conducted?
This trial has 2 study locations across California, South Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
RECRUITING · Phase 1
-
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
RECRUITING · Phase 1
-
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects
COMPLETED · Phase 1
-
Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
COMPLETED · Phase 1
-
A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.